Please login to the form below

Not currently logged in
Email:
Password:

Athenex expands global leadership team

Dr Simon Pedder and Raymond Yeung join the pharmaceutical firm

Global specialty oncology pharmaceutical company Athenex has appointed Dr Simon Pedder and Raymond Yeung to its global leadership team.

Based in the US, Dr Pedder joins as vice president of corporate strategy and business development.

He brings over 25 years of executive management experience in drug development, including as vice president of oncology pharma business at Hoffman-LaRoche, vice president and head of drug development at Shearwater Corporation and most recently as president and chief executive officer for Cellectar Biosciences.

Dr Pedder said: “Athenex has a very strong executive management team … [and] coupled with their unique business model and deep oncology portfolio, Athenex is going to be a leader in the US and China, reshaping traditional treatment options for cancer patients.

“I am looking forward to joining their leadership team to further their business and scientific strategies.”

Meanwhile, Raymond Yeung joins Athenex's Hong Kong office as its new senior director and deputy head of clinical research and regulatory affairs, Asia-Pacific.

Prior to joining the oncology specialist firm, Yeung held several senior management positions in preclinical and clinical development, including managing director of Albany Molecular Research Inc, general manager at Fortune Pharmacal and director of Asia-Pacific at MSD Pharma Services.

Yeung said: “I am delighted to come out of retirement to work with [Athenex's] leadership team to contribute towards the development of new medicine to help patients and also to bridge the biotechnology/pharmaceutical space between the US and China.”

15th February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics